Safety and efficacy of durvalumab with R-CHOP or R-2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

GS Nowakowski, W Willenbacher, Richard Greil (Co-author), TS Larsen, K Patel, U Jager, RF Manges, L Trumper, H Everaus, N Kalakonda, P Brown, JM Jorgensen, D Cunningham, J DellxxxAringa, B Fox, ND Rubio, N Kilavuz, ML Casadebaig, O Manzke, J Munoz

Research output: Contribution to journalOriginal Article (Journal)peer-review

16 Citations (Web of Science)
Original languageEnglish
JournalINTERNATIONAL JOURNAL OF HEMATOLOGY
DOIs
Publication statusPublished - 2021

Keywords

  • B-CELL LYMPHOMA
  • RITUXIMAB PLUS CYCLOPHOSPHAMIDE
  • DEATH-LIGAND 1
  • GENE-EXPRESSION
  • DOXORUBICIN
  • SURVIVAL
  • VINCRISTINE
  • SUBTYPES
  • INDUCE

Cite this